Website & contact details
- Website
Oxford Gene Technology (Operations) Ltd
- Incorporated
- 21 September 1999 (27 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Shinichi SatoKenji Iwakabe
- Accounts type
- Full
- Region
- South East
- Address
- Unit 5 Oxford Technology Park4A Technology DriveKidlingtonOX5 1GN
Filing status
- Accounts due
- 31 December 2026
- Last accounts
- 31 March 2025
- Conf. stmt due
- 26 March 2027
- Last conf. stmt
- 12 March 2026
Charges
- Total
- 1
- Outstanding
- 0
- Part satisfied
- 0
- Satisfied
- 1
Officers 5 active
Officer details are public data from the Companies House register.
Sato, Shinichi
Director · Appointed 30 April 2026
Japanese
Born April 1968 (58)
Iwakabe, Kenji
Director · Appointed 7 May 2025
Japanese
Born June 1975 (51)
Director · Appointed 28 April 2022
British
Born August 1971 (55)
Director · Appointed 30 January 2019
British
Born October 1980 (46)
Secretary · Appointed 18 May 2006
British
Officer history (21 former)
30 April 2026
Appointed Sato, Shinichi as Director
30 April 2026
31 March 2026
Resigned Matsuo, Naohiko as Director
25 September 2025
7 May 2025
Appointed Iwakabe, Kenji as Director
27 March 2025
27 March 2025
Appointed Matsuo, Naohiko as Director
27 March 2025
Resigned Ono, Takashi as Director
16 May 2024
Appointed Ono, Takashi as Director
28 March 2024
Resigned Kubota, Mamoru as Director
29 March 2023
Appointed Kubota, Mamoru as Director
29 March 2023
31 October 2022
28 April 2022
28 April 2022
31 March 2022
30 January 2019
19 October 2018
23 February 2018
18 October 2017
17 July 2017
21 June 2017
25 February 2016
31 January 2016
9 January 2012
15 January 2008
17 April 2007
18 May 2006
18 May 2006
7 September 2005
31 May 2005
1 March 2005
31 January 2002
31 January 2002
6 November 2001
Resigned Millar, Andrew, Doctor as Director
19 November 1999
19 November 1999
Appointed Millar, Andrew, Doctor as Director
19 November 1999
19 November 1999
19 November 1999
19 November 1999
23 September 1999
23 September 1999
23 September 1999
23 September 1999
21 September 1999
21 September 1999
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 6 April 2016
Owns 75–100% of shares
Holds 75–100% of voting rights
Right to appoint and remove directors
Limited Company
Reg. no. 03845467
Former controllers (1)
6 April 2016
Group structure 5 companies
Ownership group derived from the Companies House PSC register
Cytocell Limited Owns 75–100% of shares
Oxford Gene Technology (Operations) Ltd This company Owns 75–100% of shares
Oxford Gene Technology (Southern) Limited Owns 75–100% of shares
Oxford Gene Technology Limited Owns 75–100% of shares
Financials
Balance sheet as at 31 March 2025 · full accounts
- Net Assets
- (£26,298,977)
- Cash
- £4,232,826
- Turnover
- £10,348,123
- Profit Before Tax
- (£100,731)
- Employees
- 58
- Debt Ratio
- 161%
- Current Ratio
- 0.6x
- Profit Margin
- -1%
Trend
Turnover
Balance sheet detail
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Fixed Assets | £3,095,486 | £3,249,327 | £163,163 |
| Current Assets | £39,867,985 | £35,339,049 | £32,055,062 |
| Cash | £4,232,826 | £5,087,671 | £6,132,158 |
| Creditors (< 1 year) | £67,831,079 | £62,901,275 | £58,895,906 |
| Creditors (> 1 year) | £1,005,623 | £1,221,536 | |
| Net Current Assets | (£27,963,094) | (£27,562,226) | (£26,840,844) |
| Net Assets | (£26,298,977) | (£25,946,153) | (£26,704,460) |
| Shareholder Funds | (£26,298,977) | (£25,946,153) | (£26,704,460) |
| Turnover | £10,348,123 | £11,552,075 | £10,839,219 |
| Cost of Sales | £5,806,384 | £6,142,095 | £6,016,808 |
| Gross Profit | £4,541,739 | £5,409,980 | £4,822,411 |
| Admin Expenses | £5,619,911 | £5,050,550 | £4,072,681 |
| Staff Costs | £4,386,270 | £3,926,593 | £3,362,494 |
| Operating Profit | (£560,858) | £576,049 | £749,730 |
| Profit Before Tax | (£100,731) | £1,068,970 | £994,121 |
| Tax | £252,093 | £310,663 | (£56,246) |
| Profit for Period | (£352,824) | £758,307 | £1,050,367 |
What Oxford Gene Technology say about themselves
“Interrogate key biomarkers with our hybridisation-based FISH, NGS and array products for haematology, solid tumour, cytogenetics and rare disease. Learn more”
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 4 June 2026 | Appointment of a director | |||
| 30 April 2026 | Termination of appointment of a director | |||
| 30 April 2026 | Termination of appointment of a director | |||
| 12 March 2026 | Confirmation statement with no updates | 12 March 2026 | ||
| 2 December 2025 | Full accounts | 31 March 2025 |
Some other companies at this address
Other companies in this industry
Kidlington
Middlesex
Manchester
Hartley Wintney
Pampisford
Cambridge
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →